Poster Abstract Session:
58. HIV - Antiretroviral Therapy
Friday, October 21, 2011: 12:15 PM-2:15 PM
Room: Poster Hall B1

Topical Category: H. HIV/AIDS and other retroviruses

Tracks: HIV

Presentations:

401
Antiretroviral CNS Penetration Effectiveness Rank is Associated with HIV-Related Distal Sensory Polyneuropathy and Low Intraepidermal Nerve Fiber Density
Elias Skopelitis, MD ; Athanasios Kontos, MD ; George Panayiotakopoulos, MD ; Kyriaki Aroni, MD ; Panayiotis Kokotis, MD ; Kyriaki Panayiotopoulou ; Theodore Kordossis, MD

403
Analysis of Lipid Levels and Neuropsychiatric Events in Treatment-Na´ve HIV-1-Infected Adults Treated With Rilpivirine or Efavirenz Over 96 Weeks in ECHO and THRIVE
Michael Sension, MD ; Mariette Botes, MBChB ; Dan Duiculescu, MD, PhD ; Gerd Fńtkenheuer, MD ; Eric Florence, MD, PhD ; Claudio Gonsalez, MD ; Chien-Ching Hung, MD, MIH, PhD ; Franšois Raffi, MD, PhD ; Timothy Wilkin, MD, MPH ; Robin Wood, MD, PhD ; Henri Deckx ; Marita Stevens ; Simon Vanveggel, MSc ; Katia Boven, MD

404
Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Na´ve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials
Claudia Martorell, MD, MPH, FACP ; Cynthia Mayer, DO, FACOI ; Rebeca Northland, MD ; Esteban Ribera, MD ; Armin Rieger, MD ; Sharon Walmsley, MD, FRCP ; Simon Vanveggel, MSc ; Katia Boven, MD

405
Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile Through 4 Years in Treatment-na´ve Patients: 192 Week (Wk) Results from STARTMRK
Edwin DeJesus, MD, FACP ; Jurgen Rockstroh ; Jeffrey Lennox, MD ; Michael S. Saag, MD, FIDSA ; Adriano Lazzarin ; Hong Wan ; Anthony Rodgers ; Kim Strohmaier ; Hedy Teppler, MD ; Bach-Yen Nguyen ; Randi Leavitt ; Peter Sklar

406
Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral-na´ve Subjects: 96-Week Efficacy and Safety Results of the PROGRESS Study
Joseph Gathe, MD ; Jacques Reynes, MD, PhD ; Federico Pulido, MD ; Ruth Soto-Malave, MD ; Min Tian ; Linda Fredrick, MS ; Thomas Podsadecki, MD ; Angela Nilius, PhD

408
Safety and Efficacy Outcomes by N(t)RTI Background Regimen over 96 Weeks in Treatment-Na´ve HIV-1-infected Patients Treated with Rilpivirine or Efavirenz in the Phase III ECHO and THRIVE Trials
Mark Bloch, MBBS, MMed ; Lawrence R Crane, MD, FACP, FIDSA ; Jacques Reynes, MD, PhD ; Bart Rijnders, MD, PhD ; William Towner, MD ; Katarina Westling, MD, PhD ; Simon Vanveggel, MSc ; Katia Boven, MD

410
SWIFT Study: Switching from Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF) Improved Fasting Lipid Parameters While Maintaining Virologic Suppression
Edwin DeJesus, MD, FACP ; Rafael Campo, MD ; Fritz Bredeek, MD, PhD, FACP ; Hui Wang, MS Biometrics ; Lauren Dau, PharmD ; John Flaherty, PharmD ; Todd Fralich, MD

411
First-Line Antiretroviral Therapy and Lipid Profile Changes Over 24 months among HIV-infected Patients in Tanzania
Enju Liu, PHD ; Catharina Armstrong, MD ; Claudia Hawkins, MD ; Eric Aris ; Chalamilla Guerino, MD ; Donna Spiegelman, PHD ; Wafaie Fawzi, MD, MPH, DrPH

412
Etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors: comparison of two genotype algorithms
Priscila Ribeiro Pacheco, MD ; Luis Carlos Sousa, MD ; Boaventura Braz Queiroz, MD ; Marilia Turchi, MD, PhD

413
Transmitted Drug Resistance Mutations and PI-Based Antiretroviral Treatment Failure
Toshibumi Taniguchi, MD ; Jessica Grubb, MD ; Nur Onen, BSc, MBChB ; E. Turner Overton, MD

414
Analysis of Prevalence and Characteristics of Transmitted HIV-1 Drug Resistance in Primary Infections in a Cohort of Acute and Recently Infected Men in New York
Ruvandhi Nathavitharana, MD MPH ; Demetre Daskalakis, MD ; Richard Hutt, RN ; Michael Marmor, PhD ; Fred Valentine, MD

415
Prevalence of Antiretroviral Drug Resistance Mutations in Antiretroviral-Naïve HIV-1 Infected Persons in Newark, New Jersey
Amina Goodwin-Fernandez, MD ; Shobha Swaminathan, MD ; Helen Fernandes, PhD ; Sally Hodder, MD

416
Comparison of World Health Organization and Stanford Drug Resistance Criteria in HIV-1 Genotypic Testing
Toshibumi Taniguchi, MD ; Jessica Grubb, MD ; Nur Onen, BSc, MBChB ; E. Turner Overton, MD

418
Primary resistance and RAMs to antiretroviral Etravirine (ETV) in HIV-1 patients from Santos, Brazil
Eliane do Carmo Del-Duque ; Daniela Funayama ; Marcos Montani Caseiro ; Shirley Vasconcelos Komninakis

419
Detection of Drug-Resistant Minority Variants (DRMVs) of HIV-1 in Antiretroviral Treatment (ART)-Naïve Subjects through Population-Based Genotypic Resistance Testing (PBGRT)
Tirdad Zangeneh, D.O., M.A. ; Charles Hicks, MD ; Deborah McMullen, RN ; Mary Ann Fletcher, Ph.D. ; Nobel Bellosillo, MD ; Jorge Villacian, MD ; Michael Kolber, Ph.D., M.D. ; Rafael Campo, MD

421
Transmitted HIV-1 drug resistance in untreated Romanian patients
Aura Temereanca ; Luminita Ene ; Camelia Sultana ; Loredana Manolescu ; Dan Duiculescu, MD, PhD ; Simona Ruta

423
Efficacy and Hepatic Safety of Rilpivirine (RPV; TMC278) in Treatment-na´ve, HIV-1-infected Patients Co-infected with Hepatitis B and/or C: Pooled 96-week Analysis of the Phase III ECHO and THRIVE Trials
Judith Feinberg, MD ; Ezio Baraldi, MD ; Robert Finlayson, MB, BS ; Jorge Rodriguez, MD ; Hans-JŘrgen Stellbrink, MD ; Edmund Wilkins, MD ; Simon Vanveggel, MSc ; Marita Stevens ; Katia Boven, MD

424
Safety of Intravenous (IV) Midazolam for Procedural Sedation in HIV-infected Patients on Antiretroviral Therapy (ART)
Elke Backman, PharmD ; Ehrenfeld Jesse, MD, MPH ; Virginia Triant, MD, MPH ; Paul Arpino, PharmD ; Zhigang Lu, MD ; Elena Losina, PhD ; Rajesh Gandhi, MD, FIDSA

426
Effect of persistency of first-line ART regimen on clinical outcomes
James H. Willig, MD, MSPH ; Andrew Westfall, MS ; Michael J. Mugavero, MD, MHSc ; Christa Nevin, MSPH ; Riddhi Modi, MBBS, MPH ; Todd Correll, PharmD ; Amit Duggal, PharmD ; Bill Guyer, PharmD ; Michael S. Saag, MD, FIDSA ; Timothy R. Juday, PhD

427
Late-Occurring Alterations in Lymphocyte Populations in HIV-1 infected Individuals During Effective Antiretroviral Therapy
Thomas Greenough, MD ; David Damiano, PhD ; Maria Cavicchi ; Reagan Savas ; Jennifer Daly, MD ; Richard Ellison III, MD

428
High Rates of Adverse Drug Reactions to Nevirapine in Filipino HIV Patients
Arthur Dessi Roman, MD ; Katerina Leyritana, MD ; Allan Tenorio, MD ; Marissa Alejandria, MD ; Jodor Lim, MD ; Edsel Maurice Salvana, MD

429
Clinical Significance of Drug-Drug Interactions in Patients Receiving HIV Antiretroviral Therapy & Cancer Chemotherapy
Kejal Patel, PharmD ; Joan Rivington, PharmD ; Trinh Pham, PharmD ; Osama Abdelghany, PharmD ; Jeffrey Topal, MD

CME Credits:

ACPE Credits:

ACPE Number:


Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.